Phase II failures: 2008–2010
The DOI matches its Crossref record.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the decreasing success rate of drugs entering clinical trials (29) suggests that the pharmacology of target-based drug candidates predicts their therapeutic efficacy and toxicity poorly.”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [29]
In the citing paper
“In the development of pharmaceutical drugs over 80% fail to reach ‘Phase III’ effectiveness trials, even after considerable investment [4].”
From Exploratory studies to decide whether and how to proceed with full-scale evaluations of public health interventions: a systematic review of guidance (2018) · cites this paper as [4]
Citations
Cites
Still being checked.
Cited by
Items 301–400 of 624
Animal Research for Alzheimer Disease: Failures of Science and Ethics
Pippin, J. J., Cavanaugh, S. E., & Pistollato, F. (2019) · BRILL eBooks · doi:10.1163/9789004391192_021 · Cited by 16
The use of genomic variants to drive drug repurposing for chronic hepatitis B
Irham, L. M., Adikusuma, W., Perwitasari, D. A., Dania, H., Maliza, R., Faridah, I. N., Santri, I. N., Phiri, Y. V. A., & Chong, R. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101307 · Cited by 16
Evolution of precision oncology‐guided treatment paradigms
DasGupta, R., Yap, A., Yong, E. Y., & Chia, S. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1585 · Cited by 21
Burt, T., Roffel, A. F., Langer, O., Anderson, K., & DiMasi, J. A. (2022) · Clinical and Translational Science · doi:10.1111/cts.13269 · Cited by 16
Arendt‐Nielsen, L., & Curatolo, M. (2013) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2013.07.026 · Cited by 15
An assessment of R&D productivity in the pharmaceutical industry
Dimitri, N. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.09.005 · Cited by 15
Biomarker use is Associated with Reduced Clinical Trial Failure Risk in Metastatic Melanoma
Rubinger, D. A., Hollmann, S., Serdetchnaia, V., Ernst, D. S., & Parker, J. L. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.14.80 · Cited by 15
Collaboration Versus Outsourcing: The Need to Think Outside the Box
Robertson, G. M., & Mayr, L. M. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.160 · Cited by 19
The Use of Antibodies in Small-Molecule Drug Discovery
Marsden, C. J., Eckersley, S., Hebditch, M., Kvist, A. J., Milner, R. D. B., Mitchell, D., Warwicker, J., & Marley, A. E. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114527770 · Cited by 17
Curt, A. E. P., Levi, A. D., & Schwab, J. M. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0318 · Cited by 15
Human Stakeholders and the Use of Animals in Drug Development
Kramer, L. A., & Greek, R. (2018) · Business and Society Review · doi:10.1111/basr.12134 · Cited by 19
Hußtegge, M., Hoang, N. A., Rebstock, J., Monecke, A., Gockel, I., Weimann, A., Schumacher, G., Bechmann, I., Lordick, F., Kallendrusch, S., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1960729 · Cited by 17
Lead Discovery and Lead Modification
Silverman, R. B., & Holladay, M. W. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-382030-3.00002-7 · Cited by 23
LaBarge, M. A., Parvin, B., & Lorens, J. B. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.02.009 · Cited by 15
Towards a Balanced Value Business Model for Personalized Medicine: An Outlook
Koelsch, C., Przewrocka, J., & Keeling, P. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.192 · Cited by 15
Future Viable Models of Psychiatry Drug Discovery in Pharma
Rizzo, S. J. S., Edgerton, J. R., Hughes, Z. A., & Brandon, N. J. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113475871 · Cited by 14
The Life Sciences Translational Challenge: The European Perspective
Barker, R., & Scannell, J. W. (2014) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479014561340 · Cited by 18
Chromatin Remodeling in Patient‐Derived Colorectal Cancer Models
Xiang, K., Wang, E., Mantyh, J. B., Rupprecht, G., Negrete, M., Sanati, G., Hsu, C., Randon, P. M., Dohlman, A. B., Kretzschmar, K., et al. (2024) · Advanced Science · doi:10.1002/advs.202303379 · Cited by 19
Improving productivity of modern-day drug discovery
Breyer, M. D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.870150 · Cited by 14
Biological Networks and Drug Discovery—Where Do We Stand?
Geppert, T., & Koeppen, H. (2014) · Drug Development Research · doi:10.1002/ddr.21207 · Cited by 16
Zhou, X., Huntjens, D., & Gilissen, R. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12035 · Cited by 14
Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development – A Systematic Review
Martić-Kehl, M. I., Wernery, J., Folkers, G., & Schubiger, P. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137235 · Cited by 17
Modelling and simulation of placebo effect: application to drug development in schizophrenia
Reddy, V. P., Kozielska, M., de Greef, R., Vermeulen, A., & Proost, J. H. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9296-7 · Cited by 16
Ng, K. P., Manjeri, A., Lee, L. M., Chan, Z. E., Tan, C. Y., Tan, Q. D., Majeed, A., Lee, K. L., Chuah, C. T. H., Suda, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205254 · Cited by 14
Jörg, M., & Madden, K. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00022e · Cited by 15
The future of the development of medicines in idiopathic pulmonary fibrosis
Fregonese, L., & Eichler, I. (2015) · BMC Medicine · doi:10.1186/s12916-015-0480-7 · Cited by 14
Humanized mouse as a tool to predict immunotoxicity of human biologics
Yong, K. S. M., Her, Z., Tan, S. Y., Tan, W. W. S., Liu, M., Lai, F., Heng, S. M., Fan, Y., Chang, K. T. E., Wang, C.-I., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.553362 · Cited by 13
Li, S., Liu, Y., Liu, M., Wang, L., & Li, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1013803 · Cited by 15
Schatz, G. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3807 · Cited by 13
Translational pain biomarkers in the early development of new neurotherapeutics for pain management
Arendt‐Nielsen, L., Nielsen, T. A., & Gazerani, P. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.884925 · Cited by 13
Graphene-Augmented Nanofiber Scaffolds Trigger Gene Expression Switching of Four Cancer Cell Types
Kazantseva, J., Ivanov, R., Gasik, M. I., Neuman, T., & Hussainova, I. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00228 · Cited by 14
Choi, I.-S., Choi, E. Y., & Lee, I. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216889 · Cited by 17
Unlocking proteomic heterogeneity in complex diseases through visual analytics
Bhavnani, S. K., Dang, B., Bellala, G., Divekar, R. D., Visweswaran, S., Brasier, A. R., & Kurosky, A. (2015) · PROTEOMICS · doi:10.1002/pmic.201400451 · Cited by 12
Muthas, D., & Boyer, S. K. (2013) · Molecular Informatics · doi:10.1002/minf.201200088 · Cited by 13
The development speed paradox: can increasing development speed reduce R&D productivity?
Lendrem, D. W., & Lendrem, C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.09.002 · Cited by 14
van Diemen, M. P. J., Berends, C. L., Akram, N., Wezel, J., Teeuwisse, W. M., Mik, B., Kan, H. E., Webb, A., Beenakker, J. M., & Groeneveld, G. J. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.031 · Cited by 15
Serrano, G. E., Intorcia, A. J., Carew, J., Chiarolanza, G., Hidalgo, J. A., Sue, L. I., Dugger, B. N., Saxon‐LaBelle, M., Filon, J. R., Scroggins, A., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000235 · Cited by 14
Functional genomics in stem cell models: considerations and applications
Shevade, K., Peddada, S., Mader, K., & Przybyla, L. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1236553 · Cited by 14
Medical Innovation Then and Now: Perspectives of Innovators Responsible for Transformative Drugs
Xu, S., & Kesselheim, A. S. (2014) · The Journal of Law Medicine & Ethics · doi:10.1111/jlme.12176 · Cited by 13
Gómez-Verján, J. C., Estrella-Parra, E. A., Vázquez-Martínez, E. R., González‐Sánchez, I., Guerrero-Magos, G., Mendoza-Villanueva, D., Isus, L., Alfaro, A., Cerbón-Cervantes, M. A., Aloy, P., et al. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.03.010 · Cited by 12
The Scientific Problems with Using Non-Human Animals to Predict Human Response to Drugs and Disease
Greek, R., & Kramer, L. A. (2019) · BRILL eBooks · doi:10.1163/9789004391192_018 · Cited by 14
Predictive modeling for cancer drug discovery using canine models
Lucroy, M. D., & Suckow, M. A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1739644 · Cited by 12
Employing novel animal models in the design of clinically efficacious GPCR ligands
Bradley, S. J., Riaz, S. A., & Tobin, A. B. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.12.002 · Cited by 12
Yamazaki, S., Spilker, M. E., & Vicini, P. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1141895 · Cited by 13
Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging
Fecher, D., Hofmann, E., Buck, A. K., Bundschuh, R. A., Nietzer, S., Dandekar, G., Walles, T., Walles, H., Lückerath, K., & Steinke, M. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160282 · Cited by 15
Erdmann, S., Kirchner, M., Götte, H., & Kieser, M. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-01093-w · Cited by 12
Manoharan, S., & Oviya, I. R. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2305-3_3 · Cited by 11
Application of in Silico Technologies for Drug Target Discovery and Pharmacokinetic Analysis
Iwata, H. (2023) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c22-00638 · Cited by 15
Drug Targets, Target Identification, Validation, and Screening
den Broeck, W. M. M. V. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00003-1 · Cited by 12
Ishiguro, A., Yagi, S., & Uyama, Y. (2013) · Journal of Human Genetics · doi:10.1038/jhg.2013.36 · Cited by 11
Using Meta-Analysis in the Social Sciences to Improve Environmental Policy
Maki, A., Cohen, M. A., & Vandenbergh, M. P. (2017) · World sustainability series · doi:10.1007/978-3-319-67122-2_2 · Cited by 15
Ligand-receptor binding kinetics in drug design
Borisov, D. V., & Veselovsky, A. V. (2020) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20206601042 · Cited by 12
Juppet, Q., Martino, F. D., Marcandalli, E., WEIGERT, M. G., Burri, O., Unser, M. A., Brisken, C., & Sage, D. (2021) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-021-09485-4 · Cited by 14
Workman, P., & Collins, I. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00001-2 · Cited by 10
Constant, S., Huang, S., Wiszniewski, L., & Mas, C. (2013) · InTech eBooks · doi:10.5772/53391 · Cited by 15
Neelapu, N. R. R., Srimath-Tirumala-Peddinti, R. C. P. K., Nammi, D., & Pasupuleti, A. M. C. (2014) · Infectious Disorders - Drug Targets · doi:10.2174/1871526514666140321110312 · Cited by 10
Early Decision-Making in Drug Development: The Potential Role of Pharmaco-EEG and Pharmaco-Sleep
Wilson, F. J., & Danjou, P. (2015) · Neuropsychobiology · doi:10.1159/000382022 · Cited by 13
Gómez-Verján, J. C., Rodríguez‐Hernández, K. D., & Reyes‐Chilpa, R. (2017) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63930-1.00008-9 · Cited by 10
Zhang, L., Cvijic, M. E., Lippy, J., Myslik, J. C., Brenner, S. L., Binnie, A., & Houston, J. G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.02.012 · Cited by 10
Monitoring additive manufacturing based products in clinical trials
Marinakis, Y., Harms, R., & Walsh, S. T. (2017) · Translational Materials Research · doi:10.1088/2053-1613/aa80f9 · Cited by 9
Kerpel‐Fronius, S., Becker, S., Barrett, J., Brun, J., Carlesi, R. M., Chan, A., Collia, L. F., Dubois, D. J., Kleist, P., Koski, G., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00843 · Cited by 11
Park, H., Nam, M.-H., Park, J.-H., Lee, J., Hong, H.-S., Kim, T., Lee, I.-H., Shin, C.-H., Lee, S., & Seo, Y. (2024) · Biomedicines · doi:10.3390/biomedicines12112475 · Cited by 14
Development of new generation influenza vaccines
Pronker, E. S., Claassen, E., & Osterhaus, A. D. M. E. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.09.071 · Cited by 9
Review: Basics of Drug Development in Rheumatology
Mina‐Osorio, P. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39253 · Cited by 9
Establishment of Animal Models of Drug-induced Liver Injury and Analysis of Possible Mechanisms
Oda, S., & Yokoi, T. (2015) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.14-00249-2 · Cited by 9
Membrane activity of a supramolecular peptide-based chemotherapeutic enhancer
Xu, D., Jiang, L., DeRidder, L. B., Elmore, B., Bukhari, M., Qiang, W., Samways, D. S. K., & Dong, H. (2016) · Molecular BioSystems · doi:10.1039/c6mb00369a · Cited by 9
Vangala, S., Pinjari, J., Patole, P. S., Ravindran, S., Gangal, R., Wangikar, P. B., Basu, S., Ahmed, T., & Rastogi, H. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm038 · Cited by 16
Ferreira, G. S., Dijkstra, F. M., Veening-Griffioen, D. H., Boon, W., Schellekens, H., Moors, E. H. M., van Meer, P. J. K., Stuurman, F. E., & van Gerven, J. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02353-1 · Cited by 9
Taciak, B., Grochowska, A., Górczak, M., Górka, E., Skorzynski, M., Białasek, M., Rygiel, T. P., & Król, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031272 · Cited by 10
Goodwin, V. A., Hill, J. J., Fullam, J., Finning, K., Pentecost, C., & Richards, D. A. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026289 · Cited by 8
Interaction of Camptothecin with Model Cellular Membranes
Tang, P. K., Chakraborty, K., Hu, W. K., Kang, M., & Loverde, S. M. (2020) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b00541 · Cited by 9
Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology
Potter, W. Z., Mallinckrodt, C. H., & Detke, M. J. (2014) · Pharmaceutical Medicine · doi:10.1007/s40290-014-0052-8 · Cited by 8
The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models
Greek, R. (2014) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2014.516129 · Cited by 10
Preclinical Pharmacological Approaches in Drug Discovery for Chronic Pain
Whiteside, G. T., Pomonis, J. D., & Kennedy, J. D. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2015.12.002 · Cited by 10
Scientific Notebook Software: Applications for Academic Radiology
Richardson, M. L., & Amini, B. (2017) · Current Problems in Diagnostic Radiology · doi:10.1067/j.cpradiol.2017.09.005 · Cited by 8
Etablierung einer Living Biobank
Pauli, C., Moch, H., & Rubin, M. A. (2017) · Der Pathologe · doi:10.1007/s00292-017-0346-1 · Cited by 8
Regulatory aspects of small molecule drugs for heart regeneration
Rodgers, K. E., Papinska, A., & Mordwinkin, N. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.06.013 · Cited by 8
Wilde, F., Specker, E., Neuenschwander, M., Nazaré, M., Bodtke, A., & Link, A. (2014) · Molecular Diversity · doi:10.1007/s11030-014-9518-6 · Cited by 8
Tocchetti, C. G., González, A., Backs, J., Pollesello, P., Rainer, P. P., Schiattarella, G. G., Bellin, M., Begley, G., Bock-Marquette, I., Balligand, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3709 · Cited by 8
Introduction: Biomarkers in Translational and Personalized Medicine
Kumar, C., & van Gool, A. J. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734363-00003 · Cited by 6
Advancements in ultrasound-mediated drug delivery for central nervous system disorders
Chuang, C.-F., Phan, T.-N., Fan, C., Le, T.-T. V., & Yeh, C. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2438188 · Cited by 10
MHNfs: Prompting In-Context Bioactivity Predictions for Low-Data Drug Discovery
Schimunek, J., Luukkonen, S., & Klambauer, G. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02373 · Cited by 11
St, S., Bj, K., Brannan, S. K., Ak, K., van Gerven, J., Mahableshwarkar, A. R., & Gs, S. (2015) · Europe PMC (PubMed Central) · Cited by 8
Reproducibility and transparency in biomedical sciences
Gannot, G., Cutting, M., Fischer, D., & Hsu, L. (2016) · Oral Diseases · doi:10.1111/odi.12588 · Cited by 9
Stanford, N., Scharm, M., Dobson, P. D., Golebiewski, M., Hucka, M., Kothamachu, V. B., Nickerson, D. P., Owen, S., Pahle, J., Wittig, U., et al. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9736-7_17 · Cited by 7
Li, G., Xu, Y., Liu, G., Zheng, M., Zhang, X., Hang, Y., & Kang, J. (2020) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202000353 · Cited by 7
Polański, J., Bogocz, J., & Tkocz, A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.06.015 · Cited by 7
Emerging technologies and challenges for better and safer drugs
Theodosiou, M., Amir-Aslani, A., & Mégarbane, B. (2013) · Biotechnology Letters · doi:10.1007/s10529-013-1408-y · Cited by 7
Empirical Generalizations: New Laws for Digital Marketing
Wind, Y., Sharp, B. M., & Nelson-Field, K. (2013) · Journal of Advertising Research · doi:10.2501/jar-53-2-175-180 · Cited by 7
Pronker, E. S., Weenen, T. C., Commandeur, H. R., Claassen, E., & Osterhaus, A. D. M. E. (2014) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2014.04.017 · Cited by 9
Phillips, A. G., Hongaard-Andersen, P., Moscicki, R. A., Sahakian, B. J., Quirion, R., Krishnan, K., & Race, T. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu100 · Cited by 7
Structure‐based protein‐protein interaction networks and drug design
Naveed, H., & Han, J. J. (2013) · Quantitative Biology · doi:10.1007/s40484-013-0018-y · Cited by 8
The future of clinical research in oncology: where are we heading to?
Lacombe, D., & Liu, Y. (2013) · PubMed · doi:10.3978/j.issn.2304-3865.2012.11.14 · Cited by 7
Kiani, Y. S., & Jabeen, I. (2019) · Computation · doi:10.3390/computation7020026 · Cited by 8
Bergauer, T., Ruppert, T., Essioux, L., & Spleiss, O. (2016) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479016651298 · Cited by 7
Application of Population Pharmacokinetics for Preclinical Safety and Efficacy Studies
Porzio, S. (2013) · Bioanalysis · doi:10.4155/bio.13.147 · Cited by 9
Ethics and epistemology of accurate prediction in clinical research
Hey, S. P. (2014) · Journal of Medical Ethics · doi:10.1136/medethics-2013-101868 · Cited by 8
Accelerating the Drug Development Pipeline with Genome‐Scale Metabolic Network Reconstructions
Dougherty, B. V., Moutinho, T. J., & Papin, J. A. (2017) · Systems Biology · doi:10.1002/9783527696130.ch5 · Cited by 9
Chirawurah, J. D., Ansah, F., Blankson, S. O., Adikah, B., Yeboah, S. N., Amenga-Etego, L. N.-K., Awandare, G. A., & Aniweh, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-85643-6 · Cited by 6
Greek, R., & Kramer, L. A. (2019) · BRILL eBooks · doi:10.1163/9789004391192_003 · Cited by 9
Metadata
- Authors
- Arrowsmith, J.
- Affiliations
- Thomson Reuters (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04-29
- Volume
- 10
- Issue
- 5
- Pages
- 328-329
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2065540447
- Cited by
- 622
- References
- 0
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 22 · 2023: 14 · 2022: 21 · 2021: 25 · 2020: 36 · 2019: 44 · 2018: 37 · 2017: 54 · 2016: 64 · 2015: 66 · 2014: 66 · 2013: 88 · 2012: 41
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- drug development failure, clinical trial attrition, drug repurposing, translational research
- MeSH terms
- Drug Industry, Pharmaceutical Preparations, Humans, Drug Design, Treatment Failure, Clinical Trials, Phase II as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.